Study of Lactobacillus DSM17938 Probiotics to Treat Functional Constipation and Improve Gut Flora in Pregnant Women Under 28 Weeks

What This Trial Is About

Constipation is a common symptom affecting many pregnant women, characterized by difficulty or reduced frequency of bowel movements, hard stools, and feelings of incomplete evacuation. This condition can negatively impact quality of life and pregnancy outcomes. Researchers are studying functional constipation in pregnant women, focusing on the role of intestinal flora imbalance and evaluating a probiotic strain, Lactobacillus reuteri DSM17938, which has shown promise in relieving constipation symptoms in other populations but lacks data in pregnant women in China. Participants in this study are randomly assigned to one of two groups. One group receives Lactobacillus reuteri DSM17938 probiotic twice daily for four weeks, while the other group receives lactulose oral solution daily for four weeks, with dosage adjusted based on constipation severity. The study specifically targets pregnant women under 28 weeks gestation during their first and second trimesters. Both treatments are provided free of charge. During the trial, participants are monitored for the effectiveness of the probiotic on constipation symptoms over four weeks. Researchers will assess changes in bowel habits, abdominal discomfort, and intestinal flora. The study tracks adherence through scheduled visits, while also monitoring safety and any adverse effects. The total participation time corresponds to the treatment duration of four weeks, focusing on early pregnancy stages to understand the probiotics impact on functional constipation.

Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women